{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00025959", "CSN": null, "TRF": "ORD_1537940_01", "MRN": "25706121", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1257542", "clinicalId": "1258912", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1537940_01", "SampleName": "US1471012.01", "Version": "0", "Sample": {"FM_Id": "ORD_1537940_01", "SampleId": "US1471012.01", "BlockId": "S111-54088A", "TRFNumber": "ORD_1537940_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_01_05", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "20", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10013", "MRN": "48288502", "FullName": "\u738b\u81c6\u6590", "FirstName": "I Fei", "LastName": "Wang", "SubmittedDiagnosis": "Lung adenocarcinoma", "Gender": "Female", "DOB": "1973_10_21", "OrderingMD": "\u8d99\u6052\u52dd", "OrderingMDId": "109266", "Pathologist": "\u738b\u857e\u742a", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lung", "CollDate": "2022_12_23", "ReceivedDate": "2023-01-19 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Lung Adenocarcinoma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "ALK"}, {"Gene": "BRAF"}, {"Gene": "ERBB2"}, {"Gene": "KRAS"}, {"Gene": "MET"}, {"Gene": "RET"}, {"Gene": "ROS1"}]}, "Summaries": {"alterationCount": "24", "clinicalTrialCount": "28", "resistiveCount": "0", "sensitizingCount": "5"}, "VariantProperties": {"VariantProperty": [{"geneName": "APC", "isVUS": "true", "variantName": "S2296N"}, {"geneName": "BCL6", "isVUS": "true", "variantName": "E419V"}, {"geneName": "CD22", "isVUS": "true", "variantName": "A697T"}, {"geneName": "CDH1", "isVUS": "true", "variantName": "P461S"}, {"geneName": "CIC", "isVUS": "true", "variantName": "P1599S"}, {"geneName": "EGFR", "isVUS": "true", "variantName": "A86T"}, {"geneName": "MED12", "isVUS": "true", "variantName": "E227*"}, {"geneName": "MEN1", "isVUS": "true", "variantName": "G508D"}, {"geneName": "NOTCH1", "isVUS": "true", "variantName": "I567V"}, {"geneName": "NPM1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "PIK3CB", "isVUS": "true", "variantName": "L166T"}, {"geneName": "PMS2", "isVUS": "true", "variantName": "L56V"}, {"geneName": "POLE", "isVUS": "true", "variantName": "D225N"}, {"geneName": "RET", "isVUS": "true", "variantName": "V292M"}, {"geneName": "SDHA", "isVUS": "true", "variantName": "amplification"}, {"geneName": "SGK1", "isVUS": "true", "variantName": "E14G"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "APC", "Include": "true", "Alterations": {"Alteration": {"Name": "E1295*", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "2.05", "isEquivocal": "false", "name": "E1295*"}}, "Interpretation": "APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta_catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation (Logan and Nusse, 2004; 15473860). Alterations such as seen here may disrupt APC function or expression (Eklof et al., 2001; 11707392, Liu et al., 2006; 16753179, Dikovskaya et al., 2010; 20144988, Murphy et al., 2007; 17410430, Aretz et al., 2004; 15459959). APC mutations have been reported in 1.7%_4.3% of lung adenocarcinomas (Cancer Genome Atlas Research Network, 2014; 25079552, cBio_Ding et al., 2008; 18948947, cBio_Imielinski et al., 2012; 22980975) and in 1.1% of lung squamous cell carcinomas (SCCs)(Cancer Genome Atlas Research Network, 2012; 22960745). In contrast, loss of heterozygosity (LOH) at the APC/MCC locus has been reported in up to 68% (17/25) of non_small cell lung cancers (NSCLCs), with a higher incidence in SCCs compared with adenocarcinomas (Sanz_Ortega et al., 1999; 10549031, Poursoltan et al., 2012; 22542170). Hypermethylation of APC in NSCLC tumors has been reported in a number of studies (Zhang et al., 2011; 21255913, Virmani et al., 2001; 11448917, Vallb\u00f6hmer et al., 2006; 16870044, Stewart, 2014; 24309006); hypermethylation and lower APC mRNA expression have been associated with poorer survival in patients with NSCLC (Lu et al., 2006; 17194181, Poursoltan et al., 2012; 22542170). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). There are no approved drugs targeting APC inactivation in cancer. Loss of APC function leads to accumulation of beta_catenin and upregulation of WNT pathway transcription programs (Zhan et al., 2017; 27617575), and potential therapeutic approaches to target this pathway include CBP/beta_catenin antagonists, which interfere with the ability of beta_catenin to interact with transcriptional co_activator CBP (Jung et al., 2020; 32037398, Krishnamurthy and Kurzrock, 2018; 29169144). In a Phase 1 trial of the CBP/beta_catenin antagonist E7386, 1 patient with APC_mutated small bowel adenocarcinoma achieved a PR with tumor shrinkage of _69% and response duration of 165 days (Kawazoe et al., 2021; ESMO Abstract 473P); preclinical data support sensitivity of APC_deficient gastric or colorectal cancer models to E7386 (Yamada et al., 2021; 33408116, Kanda et al., 2022; 34837838). Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP) (Kerr et al., 2013; 23159591, Fearon, 2011; 21090969, Kastritis et al., 2009; 18844223). The prevalence for FAP in the general population is estimated to be 1:8,300 from birth (Half et al., 2009; 19822006), and in the appropriate clinical context germline testing of APC is recommended.", "Include": "true", "ClinicalTrialNote": "Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta_catenin interaction inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04008797", "Include": "true"}, {"nctId": "NCT03264664", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "EGFR", "Include": "true", "Alterations": {"Alteration": {"Name": "L858R", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "28.05", "isEquivocal": "false", "name": "L858R"}}, "Interpretation": "EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide (Ciardiello and Tortora, 2008; 18337605). EGFR L858 is located in the kinase domain and is encoded by exon 21. EGFR L858R has been characterized as activating (Lynch et al., 2004; 15118073, Paez et al., 2004; 15118125, Pao et al., 2004; 15329413) and patients with the L858R mutation have been shown to be sensitive to EGFR tyrosine kinase inhibitors, such as erlotinib, gefitinib (Lynch et al., 2004; 15118073, Paez et al., 2004; 15118125, Pao et al., 2004; 15329413), and afatinib (Yang et al., 2015; 25589191). EGFR mutation has been reported in 12_36% of lung adenocarcinomas (Vallee et al., 2013; 23934203, Imielinski et al., 2012; 22980975, Cancer Genome Atlas Research Network., 2014; 25079552) and in 4% of lung squamous cell carcinomas (Cancer Genome Atlas Research Network., 2012; 22960745). EGFR protein expression/overexpression has been reported in up to 70% of NSCLC cases (Watzka et al., 2010; 20353893, Liang et al., 2010; 20637128, Grob et al., 2013; 23238037, Park et al., 2012; 22207554, Dobashi et al., 2011; 21040950, Ludovini et al., 2013; 23314677). In addition, expression of EGFR protein has been shown to be higher in lung squamous cell carcinoma samples as compared to lung adenocarcinoma (Skrzypski et al., 2013; 23870818, Kim et al., 2012; 22419022). In patients with lung adenocarcinoma, EGFR mutation was a predictor of poor overall survival (Lee et al., 2013; 23525704, Oakley and Chiosea, 2011; 21587084). However, EGFR mutations have been reported to predict improved survival in patients with resected Stage 1_3 lung adenocarcinoma (Marks et al., 2008; 18303429) or resected Stage 1 NSCLC (Izar et al., 2013; 23932319). For patients with non_small cell lung cancer (NSCLC), EGFR activating mutations may predict sensitivity to EGFR\u2013TKIs, including erlotinib (Rosell et al., 2011; 22285168), gefitinib (Douillard et al., 2014; 24263064, Hayashi et al., 2020; 32673682, Cao et al., 2018; 29780256, Yang et al., 2011; 21422421), afatinib (Sequist et al., 2013; 23816960, Bao_Dong Qin et al., 2018; 30127622, Frega et al., 2016; 27131295, Long et al., 2020; 33116645), dacomitinib (Mok et al., 2018; 29864379), and osimertinib (Janne et al., 2015; 25923549, Bao_Dong Qin et al., 2018; 30127622); however, the data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). A Phase 1 study of amivantamab monotherapy or amivantamab in combination with lazertinib for the treatment of EGFR_mutated non_small cell lung cancer (NSCLC) has produced encouraging preliminary results for treatment_naive patients and patients who relapsed after treatment with osimertinib with and without chemotherapy, including osimertinib_relapsed patients with biomarkers indicating EGFR/MET_based osimertinib resistance (Park et al., 2021; 34339292, Jatkoe et al., 2022; 35963523, Petrini et al., 2022; 36246734, Bauml et al., 2021; ASCO Abstract 9006). For patients with EGFR exon 18_mutated pretreated NSCLC, the updated results from the SUMMIT basket trial of neratinib reported an ORR of 34% (10/29) and median PFS of 5.8 months, including ORRs of 30% (7/23) for TKI_pretreated patients, 50% (3/6) for TKI_naive patients, and 29% (2/7) for those with brain metastases (Goldman et al., 2022; ENA Abstract 228). A Phase 1 study showed that the MET antibody_drug conjugate telisotuzumab vedotin (teliso_V) plus osimertinib yielded an ORR of 58% (11/19) for patients with EGFR_mutated, MET_overexpressing NSCLC who progressed on osimertinib, including ORRs of 56% (5/9) for patients with EGFR L858R mutation and 67% (6/9) for those with EGFR exon 19 deletion and no response for a patient with EGFR G719S mutation (Goldman et al., 2022; ASCO Abstract 9013). In a Phase 1 trial, the HER3_targeted antibody patritumab deruxtecan elicited an ORR of 39% (22/57, 1 CR) and a median PFS of 8.2 months for patients with non_small cell lung cancer previously treated with an EGFR TKI, many of whom displayed TKI resistance alterations (Janne et al., 2022; 34548309). A Phase 1 trial evaluating the EGFR inhibitor AZD3759 reported a reduction in the volume of brain metastases in 40% (8/20) of patients with previously treated non_small cell lung cancer (NSCLC) harboring either the EGFR L858R alteration or EGFR exon 19 deletion, including 3 confirmed PRs and 3 unconfirmed PRs (Ahn et al., 2017; 29056570, Yang et al., 2016; 27928026). In a Phase 1/2 trial for advanced NSCLC, the brain_penetrant third_generation EGFR TKI lazertinib enabled ORRs of 54% (69/127) for all evaluable patients and 44% (8/18, intracranial) for patients with brain metastases (Ahn et al., 2019; 31587882). A Phase 1 trial evaluating the irreversible pan_HER inhibitor FCN_411 for NSCLC patients who had EGFR mutations and experienced disease progression on standard treatments reported an ORR of 15% with 10/67 patients achieving PR, and a DCR of 73% with 39 additional patients achieving SD (Lin et al., 2022; 35248866). OR was observed in a numerically higher proportion of patients with the EGFR T790M mutation than those without this mutation (Lin et al., 2022; 35248866). The Phase 3 AENEAS trial of first_line aumolertinib, a third_generation EGFR TKI, for patients with locally advanced or metastatic NSCLC harboring either the EGFR L858R alteration or EGFR exon 19 deletion reported significantly improved mPFS (19.3 months vs. 9.9 months) and similar ORR (74% vs. 72%) and DCR (93% vs. 97%) compared with gefitinib (Lu et al., 2022; 35580297). For patients with NSCLC treated with EGFR tyrosine kinase inhibitors, PIK3CA mutation is associated with shorter OS in a meta_analysis (pooled HR of 1.83) (Chen et al., 2015; 26175928). Clinical studies of lung cancer have shown that acquired PIK3CA mutation may confer resistance to EGFR inhibitors like osimertinib (Schoenfeld et al., 2020; 31911548, Ramalingam et al., 2018; ESMO Abstract LBA50, Papadimitrakopoulou et al., 2018; ESMO Abstract LBA51). Patients with EGFR_mutated non_squamous metastatic non_small cell lung cancer (NSCLC) who progressed on EGFR TKI have benefited from immune checkpoint inhibitors combined with antiangiogenic therapy and chemotherapy, particularly atezolizumab plus bevacizumab plus carboplatin and paclitaxel (OS HR=0.61 compared with bevacizumab/chemotherapy) (Reck et al., 2019; 30922878, Socinski et al., 2021; 34311108, Socinski et al., 2018; 29863955) or sintilimab plus bevacizumab biosimilar IBI305 plus cisplatin and pemetrexed (PFS HR=0.46 compared with chemotherapy alone) (Lu et al., 2022; 35908558).", "Include": "true", "ClinicalTrialNote": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Afatinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Afatinib is an irreversible kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4. It is FDA approved for the first_line treatment of patients with metastatic non_small cell lung cancer (NSCLC) and nonresistant EGFR mutations and for the treatment of patients with metastatic, squamous NSCLC after progression on platinum_based chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> EGFR activating mutations may indicate sensitivity to afatinib or dacomitinib for patients with non_small cell lung cancer (Sequist et al., 2013; 23816960, Wu et al., 2014; 24439929, Passaro et al., 2019; ELCC Abstract 115O, Mok et al., 2018; 29864379), whereas data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). </p> <p><b>Supporting Data:</b> In the first_line setting for patients who are EGFR TKI naive with non_small cell lung cancer (NSCLC) harboring common EGFR mutations (exon 19 or L858R alterations), afatinib has shown improved clinical benefit and responses as compared with chemotherapy in the Phase 3 LUX_Lung 3 and LUX_Lung 6 trials (Sequist et al., 2013; 23816960, Wu et al., 2014; 24439929) and to gefitinib in the Phase 2b LUX_Lung 7 trial (Park et al., 2016; 27083334, Paz_Ares et al., 2017; 28426106); these outcomes are supported in additional prospective or randomized Phase 2 trials (Popat et al., 2018; IASLC WCLC Abstract P1.13_17, Suzuki et al., 2018; IASLC WCLC Abstract P1.01_92). Alteration_specific differences in OS response have also been reported in patients who are treatment naive, with increased OS observed in patients with EGFR exon 19 alterations between afatinib and comparator arms versus no significant OS differences for patients with L858R mutations in the same treatment settings (Yang et al., 2015; 25589191, Lau et al., 2019; 31178389). In the second_line setting, patients with metastatic NSCLC and common EGFR mutations who progressed on prior chemotherapy experienced an ORR of 50% (30/60) from afatinib in a Phase 4 trial (Thongprasert et al., 2019; 31807143). A retrospective study of afatinib administered to Asian patients with NSCLC, 99% of whom were previously treated with erlotinib and/or gefitinib, reported an ORR of 27% for patients with common sensitizing EGFR mutations and an ORR of 24% for the entire cohort (Chang et al., 2018; IASLC WCLC Abstract P1.01_11). In a case report, a patient with NSCLC with exon 19 deletion and leptomeningeal metastases experienced an ongoing 16_month PR from afatinib in extracranial, brain, and leptomeningeal lesions (Llinas_Quintero et al., 2019; 31637072). For patients with erlotinib_ or gefitinib_resistant NSCLC and EGFR mutations, Phase 2/3 studies of afatinib treatment have generally reported ORRs of only 7 to 9% (Miller et al., 2012; 22452896, Chen et al., 2013; 23664448, Katakami et al., 2013; 23816963, Landi et al., 2014; 25242668, De Gr\u00e8ve et al., 2015; 25682316, Yang et al., 2015; 26051236); however, DCRs of more than 50% have been observed (De Gr\u00e8ve et al., 2015; 25682316). In a Phase 1b or observational study, patients with EGFR_mutated NSCLC who progressed on afatinib experienced further clinical benefit from subsequent treatment with afatinib and cetuximab (Horn et al., 2017; 29110849) or osimertinib (Yamamoto et al., 2020; 31863283), respectively. In the LUX_Lung 1 Phase 2b/3 trial for patients with advanced non_small cell lung cancer (NSCLC) who previously progressed on first_generation EGFR tyrosine kinase inhibitors, afatinib treatment resulted in longer median PFS (mPFS; 3.3 vs. 1.1 months, HR=0.38) but no significant difference in median OS (mOS; 10.8 vs. 12.0 months, HR=1.08) when compared with placebo (Miller et al., 2012; 22452896); similar results were observed in the single_arm LUX_Lung 4 trial in the same treatment setting (Katakami et al., 2013; 23816963). The randomized Phase 3 LUX_Lung 8 trial comparing afatinib with erlotinib as second_line therapy for advanced lung squamous cell carcinoma (SCC) reported significantly longer mOS (7.9 vs. 6.8 months, HR=0.81), significantly longer mPFS (2.6 vs. 1.9 months, HR=0.81), and higher DCR (51% vs. 40%, p=0.002) for patients treated with afatinib (Soria et al., 2015; 26156651). For patients who progressed on afatinib monotherapy, additional clinical benefit has been reported from afatinib combined with paclitaxel (Schuler et al., 2016; 26646759). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Erlotinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Erlotinib is a small_molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non_small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first_line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression (Cappuzzo et al., 2010; 20493771, Rosell et al., 2012; 22285168, Zhong et al., 2019; 31194613, Petrelli et al., 2011; 22056888). </p> <p><b>Supporting Data:</b> For patients with EGFR_mutated non_small cell lung cancer (NSCLC), the Phase 3 EURTAC trial improved PFS with first_line erlotinib relative to platinum_based chemotherapy (9.7 vs. 5.2 months, HR=0.37), though OS was not prolonged (22.9 vs 19.6 months, HR=0.92)(Rosell et al., 2012; 22285168, Leon et al., 2014; doi.org/10.1093/annonc/mdu349.52). This study and meta_analyses attribute the lack of OS benefit to the effectiveness of post_progression salvage therapy in the control arm (Lee et al., 2017; 28376144). A Phase 3 study reported similar efficacy of erlotinib and gefitinib for patients with EGFR_mutated NSCLC (Yang et al., 2017; 28103612). Patients with EGFR_mutated NSCLC have experienced PFS benefit with the addition of bevacizumab to erlotinib in the first_line setting in Phase 3 trials including the ARTEMIS_CTONG1509 trial for Chinese patients (17.9 vs. 11.2 months, HR=0.55)(Zhou et al., 2021; 34388377), the NEJ026 trial for Japanese patients (16.9 vs. 13.3 months, HR=0.605)(Kawashima et al., 2022; 34454653, Saito et al., 2019; 30975627), and the international BEVERLY trial (15.4 vs. 9.7 months, HR=0.60)(Piccirillo et al., 2021; ESMO Abstract 12070); OS benefit has not been observed across these studies. In the maintenance setting, Phase 3 trials have reported significantly improved PFS with maintenance erlotinib following first_line platinum_based chemotherapy, with the largest benefit for patients with EGFR mutations (Cappuzzo et al., 2010; 20493771, Faehling et al., 2018; 29687154). In the neoadjuvant setting, a Phase 2 trial reported a numerically improved ORR and significantly longer PFS with erlotinib compared with chemotherapy for patients with EGFR_mutated advanced NSCLC (Zhong et al., 2019; 31194613). In the placebo_controlled Phase 3 RELAY trial, the addition of ramucirumab to erlotinib improved PFS for previously untreated patients with NSCLC harboring EGFR L858R or exon 19 deletion (19.4 vs. 12.4 months, HR=0.59)(Nakagawa et al., 2019; 31591063). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Osimertinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI_sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non_small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> EGFR TKI_sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non_small cell lung cancer (Janne et al., 2015; 25923549, Soria et al., 2018; 29151359, Alanazi et al., 2020; 33318755, Kim et al., 2021; DOI: 10.1200/PO.20.00296, Wang et al., 2018; 30255937). Patients with untreated advanced NSCLC and EGFR exon 19 deletions or L858R mutations achieved an ORR of 80% and a median PFS of 21.4 and 14.4 months, respectively (Soria et al., 2018; 29151359). </p> <p><b>Supporting Data:</b> The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first_line osimertinib significantly increased both median PFS (mPFS; 18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced non_small cell lung cancer (NSCLC) and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858) (Soria et al., 2018; 29151359, Ramalingam et al., 2019; 31751012). In the Phase 3 ADAURA study, patients with early_stage (IB/II/IIIA) EGFR_mutated NSCLC experienced longer disease_free survival on osimertinib compared with placebo in the adjuvant setting (65.8 vs. 28.1 months, HR=0.27) (Tsuboi et al., 2022; ESMO Abstract LBA47). A Phase 1 study reported that T790M_negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months (Janne et al., 2015; 25923549). A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR_mutated, T790M_negative NSCLC reported an ORR of 19% (4/21), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non_small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213) (Kenmotsu et al., 2022; 35636696). The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR_sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47) (Soo et al., 2021; ESMO Abstract VP3_2021). The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR_mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively (Oxnard et al., 2020; 32139298). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Gefitinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non_small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR_mutated non_small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy (Han et al., 2012; 22370314, Maemondo et al., 2010; 20573926, Mitsudomi et al., 2010; 20022809, Mok et al., 2009; 19692680, Petrelli et al., 2011; 22056888, Qi et al., 2015; 25329826, Zhao et al., 2015; 25546556), and responses have been reported for patients with EGFR_rearranged NSCLC (Wang et al., 2018; 30255937, Baik et al., 2015; 26398831). </p> <p><b>Supporting Data:</b> Gefitinib achieved an ORR of 69.8% and OS of 19.2 months as first_line treatment for Caucasian patients with non_small cell lung cancer (NSCLC) and EGFR sensitizing mutations (Douillard et al., 2014; 24263064). Phase 3 studies for Japanese patients (Mitsudomi et al., 2010; 20022809, Yoshioka et al., 2019; 31553438) and East Asian patients (Fukuoka et al., 2011; 21670455, Mok et al., 2009; 19692680) with EGFR_mutated NSCLC reported longer PFS but not longer OS on first_line gefitinib compared with cisplatin and docetaxel or carboplatin and paclitaxel. Retrospective analysis of East Asian patients receiving first_line gefitinib reported greatest PFS benefit among patients with EGFR exon 19 insertions or deletions and shortest PFS for those with exon 20 insertions (1.2 months)(Sutiman et al., 2017; 27908825). Two Phase 3 trials of the combination gefitinib plus pemetrexed and carboplatin compared with gefitinib alone for patients with advanced NSCLC harboring EGFR activating mutations reported significantly higher ORRs (75.3% and 84% vs. 62.5% and 67%), longer median PFS (16 and 20.9 months vs. 8 and 11.9 months), and longer median OS (50.9 months and not reached vs. 17 and 38.8 months) with combination treatment; however, combination treatment was associated with increased Grade 3 or higher adverse events (Noronha et al., 2019; 31411950, Hosomi et al., 2020; 31682542). In a Phase 1 study for treatment_naive patients with NSCLC, 63% (19/30) of patients experienced PR from the combination of gefitinib and the PD_L1 inhibitor durvalumab (Creelan et al., 2021; 33012782). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Dacomitinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Dacomitinib is a second generation irreversible tyrosine kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4/HER4. It is FDA approved for the first_line treatment of patients with metastatic non_small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> EGFR activating mutations may indicate sensitivity to afatinib or dacomitinib for patients with non_small cell lung cancer (Sequist et al., 2013; 23816960, Wu et al., 2014; 24439929, Passaro et al., 2019; ELCC Abstract 115O, Mok et al., 2018; 29864379), whereas data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). Patients with untreated advanced NSCLC and EGFR L858R mutations achieved an ORR of 73% (68/93) (Wu et al., 2017; 28958502) and a median OS of 32.5 months with dacomitinib (Mok et al., 2018; 29864379). </p> <p><b>Supporting Data:</b> A randomized Phase 3 trial for patients with non_small cell lung cancer (NSCLC) harboring activating EGFR mutations (primarily L858R or exon 19 deletions) reported improved clinical benefit with first_line dacomitinib compared with gefitinib (median OS [mOS] of 34.1 vs. 26.8 months, HR=0.760; median PFS [mPFS] of 14.7 vs. 9.2 months, HR=0.59) (Mok et al., 2018; 2986437, Wu et al., 2017; 28958502); mOS was 34.1 to 36.7 months and ORR was 75% to 79%, depending on the dosing regimen (Wu et al., 2018; WCLC abstract MA26.11). A pooled subgroup analysis for patients with NSCLC harboring activating EGFR mutations reported improved clinical efficacy with dacomitinib treatment compared with erlotinib (mPFS of 14.6 vs. 9.6 months, HR=0.717; mOS of 26.6 vs. 23.2 months, HR=0.737) (Ramalingam et al., 2016; 26768165). An analysis of dacomitinib in NSCLC comparing common activating EGFR alterations alone with co_occurring common and uncommon EGFR mutations showed no statistically significant difference in total ORR (33% vs. 40%, p=0.636) or DCR (77% vs. 73%, p=0.089); however, multivariate analysis revealed compound mutation status as an independent predictor of worse OS (HR=5.405) (Li et al., 2022; 35693621). A Phase 1 trial of combination dacomitinib and a MEK1/2 inhibitor for patients with KRAS_mutated CRC, NSCLC, or pancreatic cancer reported 20/36 SDs and 16 PDs, however toxicity from this combination prevented long_term treatment in this patient population (van Geel et al., 2020; 32147669). Phase 1/2 studies of dacomitinib for patients with advanced KRAS_wildtype non_small cell lung cancer (NSCLC) who had previously progressed on chemotherapy and erlotinib or gefitinib and were not selected for EGFR mutations reported ORRs of 4.6_17% (3/66_9/53), median PFS of 3_4 months, and median OS of 9_11 months (Reckamp et al., 2014; 24501009, Park et al., 2014; 25521398). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT05338970", "Include": "true"}, {"nctId": "NCT05120349", "Include": "true"}, {"nctId": "NCT04988295", "Include": "true"}, {"nctId": "NCT02609776", "Include": "true"}, {"nctId": "NCT03974022", "Include": "true"}, {"nctId": "NCT04077463", "Include": "true"}, {"nctId": "NCT04862780", "Include": "true"}, {"nctId": "NCT05215548", "Include": "true"}, {"nctId": "NCT04721015", "Include": "true"}, {"nctId": "NCT03114319", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PIK3CA", "Include": "true", "Alterations": {"Alteration": [{"Name": "G118D", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "41.04", "isEquivocal": "false", "name": "G118D"}}, "Interpretation": "PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007, Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477, Jin et al., 2021; 34779417). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the TCGA datasets, PIK3CA mutation was observed in 8.2% of lung adenocarcinoma cases (cBio_Campbell et al., 2016; 27158780) and in 15.7% of lung squamous cell carcinoma cases (Cancer Genome Atlas Research Network., 2012; 22960745). The prognostic significance of PIK3CA mutation or overexpression in NSCLC is unclear, with several studies reporting contradictory data, which may be influenced by the specific PIK3CA mutation, histologic subtype, and the presence of concurrent mutations in oncogenes such as EGFR and KRAS (Zhao et al., 2014; 24328409, Eng et al., 2015; 26334752, Song et al., 2016; 27554588, Zhang et al., 2013; 23674897, McGowan et al., 2017; 28024696, Wang et al., 2015; 26107237). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038, Canaud et al., 2021; ESMO Abstract LBA23, Delestre et al., 2021; 34613809, Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108, Santin et al., 2020; 31934607, Damodaran et al., 2022; 35133871), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Varnier et al., 2019; 31351267, Basse et al., 2018; 32914004, Sultova et al., 2021; 33277683, Mackay et al., 2014; 24166148, Myers et al., 2016; 27016228, Dhami et al., 2018; 29588307, Harris et al., 2019; 30863722, Hanna et al., 2018; 29301825). The Phase 2 NCI_MATCH study of copanlisib for patients with refractory solid tumors harboring PIK3CA mutations with or without PTEN loss met its primary endpoint with an ORR of 16% (4/25 PRs); responses (PR or SD >6 months) were seen in patients with ameloblastoma, liposarcoma, and carcinomas of the endometrium, ovary, esophagus, lung, and prostate (Damodaran et al., 2022; 35133871). However, the Phase 2 study of copanlisib for patients with endometrial carcinoma harboring PIK3CA hotspot mutations failed to report any objective responses (n=11)(Santin et al., 2020; 31934607). Two other studies of copanlisib for patients with genomically unselected tumors reported 1 CR and 2 PRs (1 unconfirmed) among 16 total patients with PIK3CA_mutated solid tumors with or without PTEN alterations (Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108). A Phase 2 study of buparlisib in NSCLC observed 2 PRs (3.2%; 2/63) in PIK3CA_pathway activated tumors, although the study did not meet its primary endpoint (Vansteenkiste et al., 2015; 26098748). For patients with NSCLC treated with EGFR tyrosine kinase inhibitors, PIK3CA mutation is associated with shorter OS in a meta_analysis (pooled HR of 1.83) (Chen et al., 2015; 26175928). Clinical studies of lung cancer have shown that acquired PIK3CA mutation may confer resistance to EGFR inhibitors like osimertinib (Schoenfeld et al., 2020; 31911548, Ramalingam et al., 2018; ESMO Abstract LBA50, Papadimitrakopoulou et al., 2018; ESMO Abstract LBA51).", "Include": "true", "ClinicalTrialNote": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04526470", "Include": "true"}, {"nctId": "NCT05125523", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}]}}, {"Name": "M1004I", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "4.39", "isEquivocal": "false", "name": "M1004I"}}, "Interpretation": "PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007, Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477, Jin et al., 2021; 34779417). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the TCGA datasets, PIK3CA mutation was observed in 8.2% of lung adenocarcinoma cases (cBio_Campbell et al., 2016; 27158780) and in 15.7% of lung squamous cell carcinoma cases (Cancer Genome Atlas Research Network., 2012; 22960745). The prognostic significance of PIK3CA mutation or overexpression in NSCLC is unclear, with several studies reporting contradictory data, which may be influenced by the specific PIK3CA mutation, histologic subtype, and the presence of concurrent mutations in oncogenes such as EGFR and KRAS (Zhao et al., 2014; 24328409, Eng et al., 2015; 26334752, Song et al., 2016; 27554588, Zhang et al., 2013; 23674897, McGowan et al., 2017; 28024696, Wang et al., 2015; 26107237). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038, Canaud et al., 2021; ESMO Abstract LBA23, Delestre et al., 2021; 34613809, Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108, Santin et al., 2020; 31934607, Damodaran et al., 2022; 35133871), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Varnier et al., 2019; 31351267, Basse et al., 2018; 32914004, Sultova et al., 2021; 33277683, Mackay et al., 2014; 24166148, Myers et al., 2016; 27016228, Dhami et al., 2018; 29588307, Harris et al., 2019; 30863722, Hanna et al., 2018; 29301825). The Phase 2 NCI_MATCH study of copanlisib for patients with refractory solid tumors harboring PIK3CA mutations with or without PTEN loss met its primary endpoint with an ORR of 16% (4/25 PRs); responses (PR or SD >6 months) were seen in patients with ameloblastoma, liposarcoma, and carcinomas of the endometrium, ovary, esophagus, lung, and prostate (Damodaran et al., 2022; 35133871). However, the Phase 2 study of copanlisib for patients with endometrial carcinoma harboring PIK3CA hotspot mutations failed to report any objective responses (n=11)(Santin et al., 2020; 31934607). Two other studies of copanlisib for patients with genomically unselected tumors reported 1 CR and 2 PRs (1 unconfirmed) among 16 total patients with PIK3CA_mutated solid tumors with or without PTEN alterations (Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108). A Phase 2 study of buparlisib in NSCLC observed 2 PRs (3.2%; 2/63) in PIK3CA_pathway activated tumors, although the study did not meet its primary endpoint (Vansteenkiste et al., 2015; 26098748). For patients with NSCLC treated with EGFR tyrosine kinase inhibitors, PIK3CA mutation is associated with shorter OS in a meta_analysis (pooled HR of 1.83) (Chen et al., 2015; 26175928). Clinical studies of lung cancer have shown that acquired PIK3CA mutation may confer resistance to EGFR inhibitors like osimertinib (Schoenfeld et al., 2020; 31911548, Ramalingam et al., 2018; ESMO Abstract LBA50, Papadimitrakopoulou et al., 2018; ESMO Abstract LBA51).", "Include": "true", "ClinicalTrialNote": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04526470", "Include": "true"}, {"nctId": "NCT05125523", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}]}}]}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 1_2", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 1_2"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). Studies have reported PTEN mutations in 6.7% (12/178) to 10% (6/59) of lung squamous cell carcinomas (Cancer Genome Atlas Research Network, 2012; 22960745, Jin et al., 2010; 20018398) but less frequently in lung adenocarcinomas (1.1_2.2%) (cBio_Rizvi et al., 2018; 29337640, Jin et al., 2010; 20018398, cBio_Ding et al., 2008; 18948947, Cancer Genome Atlas Research Network, 2014; 25079552, cBio_Imielinski et al., 2012; 22980975). Loss of PTEN expression by IHC was reported in up to 35% of NSCLC cases in one study, with several studies reporting more frequent loss of PTEN in squamous cell lung carcinoma compared to lung adenocarcinoma (O Byrne et al., 2011; 21782507, Spoerke et al., 2012; 23136191, Yanagawa et al., 2012; 22982652, Cumberbatch et al., 2013; 24284056). Loss of PTEN protein expression has been identified as a marker of poor prognosis in NSCLC (O Byrne et al., 2011; 21782507, Yanagawa et al., 2012; 22982652). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K_AKT_mTOR pathway. However, limited studies in prostate cancer (Templeton et al., 2013; 23582881, Sweeney et al., 2021; 34246347, de Bono et al., 2019; 30037818, Saura et al., 2017; 27872130), renal cell carcinoma (Voss et al., 2019; 30327302), breast cancer (Andre et al., 2016; 27091708, Dent et al., 2018; ASCO Abstract 1008, Schmid et al., 2020; 31841354), and colorectal cancer (Gilcrease et al., 2019; 30302599) have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K_AKT_mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04380636", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04497116", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT04972110", "Include": "true"}, {"nctId": "NCT04317105", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_H is generally infrequent in NSCLC, reported in fewer than 1% of samples across several large studies (Warth et al., 2016; 26637197, Ninomiya et al., 2006; 16641899, Vanderwalde et al., 2018; 29436178, Zang et al., 2019; 31270941, Dudley et al., 2016; 26880610, Takamochi et al., 2017; 28676214, Schrock et al., 2017; https://doi.org/10.1016/j.jtho.2016.11.487), whereas data on the reported incidence of MSI_H in SCLC has been limited and conflicting (Pylkkanen et al., 1997; 9329646, Gonzalez et al., 2000; 11061602, Chen et al., 1996; 8782463, Merlo et al., 1994; 8174113). One study reported MSI_H in lung adenocarcinoma patients with smoking history, and 3 of 4 MSI_H patients examined also had metachronous carcinomas in other organs, although this has not been investigated in large scale studies (Warth et al., 2016; 26637197). Published data investigating the prognostic implications of MSI in NSCLC are limited (PubMed, Oct 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RB1", "Include": "true", "Alterations": {"Alteration": {"Name": "loss exons 14_27", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "loss exons 14_27"}}, "Interpretation": "RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (Burkhart and Sage, 2008; 18650841, Knudsen and Knudsen, 2008; 19143056). Alterations such as seen here may disrupt RB1 function or expression (Berge et al., 2010; 20594292, Giacinti et al., 2006; 16936740, Otterson et al., 1997; 9342358, Otterson et al., 1999; 10486322, Qin et al., 1992; 1534305, Rubin et al., 2005; 16360038, Sun et al., 2006; 16449662). RB1 mutations have been reported in 4.5% of lung squamous cell carcinoma (SCC) cases (Cancer Genome Atlas Research Network, 2012; 22960745) and 3.5% of lung adenocarcinoma cases (Cancer Genome Atlas Research Network, 2014; 25079552). One study found that RB1 expression was correlated with poor prognosis for patients with NSCLC (Zhao et al., 2012; 22619677). On the basis of limited clinical data (Owonikoko et al., 2016; ESMO Abstract 14230) and strong preclinical data (Hook et al., 2012; 22222631, Gong et al., 2019; 30373917, Oser et al., 2019; 30373918, Yang et al., 2022; 34741392), RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer (SCLC). A clinical study evaluating the Aurora kinase A inhibitor alisertib for patients with prostate cancer did not find an association between RB1 deletion and clinical benefit (Beltran et al., 2019; 30232224). Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL_2 family members (Allaman_Pillet et al., 2013; 21955141) and activation of the NOTCH pathway (Viatour et al., 2011; 21875955). Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year (Chen et al., 2014; 24282159). Germline mutations in RB1 account for approximately 40% of RB tumors (Yun et al., 2011; 22553621) and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma (Houston et al., 2011; 21139478, Ng et al., 2010; 19959033). In the appropriate clinical context, germline testing of RB1 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "08", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "08"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Spigel et al., 2016; ASCO Abstract 9017, Hellmann et al., 2018; AACR Abstract CT077, Ramalingam et al., 2018; AACR Abstract CT078, Kowanetz et al., 2016; ESMO Abstract 77P, Gandara et al., 2017; ESMO Abstract 12950, Legrand et al., 2018; ASCO Abstract 12000, Velcheti et al., 2018; ASCO Abstract 12001, Herbst et al., 2019; ESMO Abstract LBA79, Peters et al., 2019; AACR Abstract CT07, Castellanos et al., 2019; ASCO Abstract 2630, Rizvi et al., 2015; 25765070, Colli et al., 2016; 27197178, Goodman et al., 2017; 28835386, Wang et al., 2017; 28923100, Carbone et al., 2017; 28636851, Rizvi et al., 2018; 29337640, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Forde et al., 2018; 29658848, Ready et al., 2019; 30785829, Samstein et al., 2019; 30643254, Miao et al., 2018; 30150660, Chae et al., 2019; 30425022, Marabelle et al., 2020; 32919526). A large_scale genomic analysis found that unspecified lung non_small cell lung carcinoma (NSCLC), lung adenocarcinoma, and lung squamous cell carcinoma (SCC) samples harbored median TMBs between 6.3 and 9 Muts/Mb, and 12% to 17% of cases had an elevated TMB of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Lower TMB is observed more commonly in NSCLCs harboring known driver mutations (EGFR, ALK, ROS1, or MET) with the exception of BRAF or KRAS mutations, which are commonly observed in elevated TMB cases (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and mutational burden in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong association with increased TMB (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). TMB >10 muts/Mb was found to be more frequent in NSCLC metastases compared with primary tumors for both adenocarcinoma (38% vs. 25%) and SCC (41% vs. 35%) subtypes (Stein et al., 2019; DOI: 10.1200/PO.18.00376). A meta_analysis of 19 studies of immune checkpoint inhibitor_treated NSCLC (n = 2,315 patients) demonstrated that high TMB predicted a significantly longer OS than low TMB (HR = 0.70), and within the high TMB group, immunotherapy was associated with an improved PFS (HR = 0.62, P<0.001), OS (HR = 0.67, P<0.001) and a higher response rate (OR = 2.35, P<0.001) compared to chemotherapy (Meng et al., 2022; 35113949). In contrast, a large study of Chinese patients with untreated lung adenocarcinoma reported a shorter median OS for tumors with a higher number of mutations in a limited gene set compared with a lower mutation number (48.4 vs. 61.0 months)(Xiao et al., 2016; 27009843). Another study of patients with NSCLC treated with EGFR inhibitors or platinum doublet chemotherapy found elevated TMB to be correlated with poorer prognosis, as well as finding lower TMB in combination with PD_L1 negative status to be significantly associated with longer median survival in patients with lung adenocarcinoma (Chen et al., 2019; 31088500). However, no significant prognostic association of TMB and/or PD_L1 status with survival has been reported in patients with lung SCC (Yu et al., 2019; 30253973, Chen et al., 2019; 31088500). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). Multiple clinical trials of PD_1_ or PD_L1_targeting immune checkpoint inhibitors or combination of PD_1 and CTLA_4 inhibitors in NSCLC have reported that patients with tumors harboring TMB \u226510 Muts/Mb derive greater clinical benefit from these therapies than those with TMB <10 Muts/Mb (based on this assay or others); similarly, higher efficacy of anti_PD_1 or anti_PD_L1 immunotherapy for treatment of patients with NSCLC, compared with the use of chemotherapy, has been observed more significantly in cases of TMB \u226510 Muts/Mb (based on this assay or others); (Spigel et al., 2016; ASCO Abstract 9017, Hellmann et al., 2018; AACR Abstract CT077, Ramalingam et al., 2018; AACR Abstract CT078, Kowanetz et al., 2016; ESMO Abstract 77P, Gandara et al., 2017; ESMO Abstract 12950, Legrand et al., 2018; ASCO Abstract 12000, Velcheti et al., 2018; ASCO Abstract 12001, Herbst et al., 2019; ESMO Abstract LBA79, Peters et al., 2019; AACR Abstract CT07, Castellanos et al., 2019; ASCO Abstract 2630, Rizvi et al., 2015; 25765070, Colli et al., 2016; 27197178, Goodman et al., 2017; 28835386, Wang et al., 2017; 28923100, Carbone et al., 2017; 28636851, Rizvi et al., 2018; 29337640, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Forde et al., 2018; 29658848, Ready et al., 2019; 30785829, Samstein et al., 2019; 30643254, Miao et al., 2018; 30150660, Chae et al., 2019; 30425022). Improved OS of patients with NSCLC treated with pembrolizumab plus chemotherapy relative to chemotherapy only (Paz_Ares et al., 2019; ESMO Abstract LBA80), or those treated with nivolumab plus ipilimumab also relative to chemotherapy (Hellmann et al., 2019; 31562796), has been observed across all TMB levels.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "APC", "Alteration": "E1295*", "Title": "A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor", "StudyPhase": "PHASE 1", "Target": "CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Kurume (Japan), Matsuyama (Japan), Seodaemun (Korea, Republic of), Osakasayama (Japan), Nagoya (Japan), Chuo_Ku (Japan), Koto_ku (Japan), Chiba (Japan), Kashiwa (Japan), Hidaka (Japan)", "NCTID": "NCT04008797", "Note": "Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta_catenin interaction inhibitors.", "Include": "true"}, {"Gene": "APC", "Alteration": "E1295*", "Title": "Study of E7386 in Participants With Selected Advanced Neoplasms", "StudyPhase": "PHASE 1", "Target": "CBP, Beta_catenin", "Locations": "Glasgow (United Kingdom), Manchester (United Kingdom), Sutton (United Kingdom)", "NCTID": "NCT03264664", "Note": "Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta_catenin interaction inhibitors.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "HERTHENA_Lung02: A Study of Patritumab Deruxtecan Versus Platinum_based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy", "StudyPhase": "PHASE 3", "Target": "ERBB3", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Kaohsiung City (Taiwan), Kumamoto (Japan), Kurume (Japan), Fukuoka (Japan), Goyang (Korea, Republic of), Cheongju_si (Korea, Republic of)", "NCTID": "NCT05338970", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2_IA3 NSCLC Following Complete Tumour Resection", "StudyPhase": "PHASE 3", "Target": "EGFR", "Locations": "Taipei (Taiwan), Taipei City (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Shanghai (China), Suzhou (China), Nanjing (China), Yangzhou (China), Guangzhou (China)", "NCTID": "NCT05120349", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "A Study of Amivantamab and Lazertinib in Combination With Platinum_Based Chemotherapy Compared With Platinum_Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)_Mutated Locally Advanced or Metastatic Non_ Small Cell Lung Cancer After Osimertinib Failure", "StudyPhase": "PHASE 3", "Target": "MET, EGFR", "Locations": "Taipei (Taiwan), Taichung (Taiwan), Changhua (Taiwan), New Taipei City (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Linhai (China), Hangzhou (China), Shanghai (China), Hang Zhou (China)", "NCTID": "NCT04988295", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "A Dose Escalation Study of JNJ_61186372 in Participants With Advanced Non_Small Cell Lung Cancer", "StudyPhase": "PHASE 1", "Target": "MET, EGFR", "Locations": "Taipei (Taiwan), Taipei City (Taiwan), Taichung (Taiwan), Kaohsiung (Taiwan), Hangzhou (China), Nanchang (China), Nanjing (China), Hefei (China), Guangzhou (China), Changsha (China)", "NCTID": "NCT02609776", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non_small Cell Lung Cancer With EGFR or HER2 Mutation (WU_KONG1)", "StudyPhase": "PHASE 1/2", "Target": "ERBB2, EGFR", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Liuying (Taiwan), Tainan (Taiwan), Cheonju (Korea, Republic of), Suwon (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang (Korea, Republic of)", "NCTID": "NCT03974022", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "A Study of Lazertinib as Monotherapy or in Combination With JNJ_61186372 in Japanese Participants With Advanced Non_small Cell Lung Cancer", "StudyPhase": "PHASE 1", "Target": "EGFR, MET", "Locations": "Taipei City (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Hang Zhou (China), Shanghai (China), Guangzhou (China), Changsha (China), Wuhan (China), Jinan (China)", "NCTID": "NCT04077463", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "Study Targeting EGFR Resistance Mechanisms in NSCLC", "StudyPhase": "PHASE 1/2", "Target": "EGFR", "Locations": "Taipei (Taiwan), Seoul (Korea, Republic of), Yokohama_shi (Japan), Chuo Ku (Japan), Kashiwa (Japan), Singapore (Singapore), Amsterdam (Netherlands), Sutton (United Kingdom), Villejuif (France), Toulouse (France)", "NCTID": "NCT04862780", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "Primary Tumor Resection With EGFR TKI for Stage IV NSCLC", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2", "Locations": "Taipei (Taiwan)", "NCTID": "NCT05215548", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "Study of Intravenous (IV) ABBV_637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors", "StudyPhase": "PHASE 1", "Target": "EGFR", "Locations": "Taoyuan City (Taiwan), Tainan (Taiwan), Hsinchu City (Taiwan), Kaohsiung (Taiwan), Fukuoka_shi (Japan), Seoul (Korea, Republic of), Matsuyama_shi (Japan), Goyang (Korea, Republic of), Nagoya_shi (Japan), Chuo_ku (Japan)", "NCTID": "NCT04721015", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "EGFR", "Alteration": "L858R", "Title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "SHP2, EGFR", "Locations": "Taipei (Taiwan), Seoul (Korea, Republic of), Kobe_shi (Japan), Singapore (Singapore), Amsterdam (Netherlands), Rotterdam (Netherlands), Barcelona (Spain), Hospitalet de LLobregat (Spain), Madrid (Spain), Toronto (Canada)", "NCTID": "NCT03114319", "Note": "EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha, RAFs, NRAS", "Locations": "Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China)", "NCTID": "NCT04589845", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "Alpelisib and Paclitaxel in PIK3CA_altered Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_alpha", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of)", "NCTID": "NCT04526470", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "mTOR", "Locations": "Tianjin (China)", "NCTID": "NCT05125523", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "G118DM1004I", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non_Small Cell Lung Cancer (NSCLC) (MK_7339_012/KEYLYNK_012)", "StudyPhase": "PHASE 3", "Target": "PD_L1, PARP, PD_1", "Locations": "Fuzhou (China), Xiamen (China), Hangzhou (China), Shanghai (China), Shangai (China), Nanchang (China), Shenzhen (China), Nanjing (China), Changsha (China), Wuhan (China)", "NCTID": "NCT04380636", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "Study of RP_3500 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP", "Locations": "Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Illinois, Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee", "NCTID": "NCT04497116", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "Study of RP_3500 With Niraparib or Olaparib in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PARP, ATR", "Locations": "Utah, Minnesota, Michigan, Connecticut, New York, Maryland, Texas", "NCTID": "NCT04972110", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "loss exons 1_2", "Title": "Testing the Addition of an Anti_cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN", "StudyPhase": "PHASE 1/2", "Target": "PD_1, CTLA_4, PI3K", "Locations": "Toronto (Canada), Texas, Virginia", "NCTID": "NCT04317105", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "18337605", "FullCitation": "Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605", "Include": "true"}, {"number": "1", "ReferenceId": "15118073", "FullCitation": "Lynch TJ, et al. N. Engl. J. Med. (2004) pmid: 15118073", "Include": "true"}, {"number": "2", "ReferenceId": "15118125", "FullCitation": "Paez JG, et al. Science (2004) pmid: 15118125", "Include": "true"}, {"number": "3", "ReferenceId": "15329413", "FullCitation": "Pao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2004) pmid: 15329413", "Include": "true"}, {"number": "4", "ReferenceId": "25589191", "FullCitation": "Yang JC, et al. Lancet Oncol. (2015) pmid: 25589191", "Include": "true"}, {"number": "5", "ReferenceId": "23934203", "FullCitation": "Vallee A, et al. Int. J. Oncol. (2013) pmid: 23934203", "Include": "true"}, {"number": "6", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "7", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "8", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "9", "ReferenceId": "20353893", "FullCitation": "Watzka SB, et al. Eur J Cardiothorac Surg (2010) pmid: 20353893", "Include": "true"}, {"number": "10", "ReferenceId": "20637128", "FullCitation": "Liang Z, et al. BMC Cancer (2010) pmid: 20637128", "Include": "true"}, {"number": "11", "ReferenceId": "23238037", "FullCitation": "Grob TJ, et al. Lung Cancer (2013) pmid: 23238037", "Include": "true"}, {"number": "12", "ReferenceId": "22207554", "FullCitation": "Park S, et al. Histol. Histopathol. (2012) pmid: 22207554", "Include": "true"}, {"number": "13", "ReferenceId": "21040950", "FullCitation": "Dobashi Y, et al. Hum. Pathol. (2011) pmid: 21040950", "Include": "true"}, {"number": "14", "ReferenceId": "23314677", "FullCitation": "Ludovini V, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23314677", "Include": "true"}, {"number": "15", "ReferenceId": "23870818", "FullCitation": "Skrzypski M, et al. Clin Lung Cancer (2013) pmid: 23870818", "Include": "true"}, {"number": "16", "ReferenceId": "22419022", "FullCitation": "Kim SH, et al. Histol. Histopathol. (2012) pmid: 22419022", "Include": "true"}, {"number": "17", "ReferenceId": "23525704", "FullCitation": "Lee JS, et al. Ann. Surg. Oncol. (2013) pmid: 23525704", "Include": "true"}, {"number": "18", "ReferenceId": "21587084", "FullCitation": "Oakley GJ, et al. J Thorac Oncol (2011) pmid: 21587084", "Include": "true"}, {"number": "19", "ReferenceId": "18303429", "FullCitation": "Marks JL, et al. J Thorac Oncol (2008) pmid: 18303429", "Include": "true"}, {"number": "20", "ReferenceId": "23932319", "FullCitation": "Izar B, et al. Ann. Thorac. Surg. (2013) pmid: 23932319", "Include": "true"}, {"number": "21", "ReferenceId": "22285168", "FullCitation": "Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168", "Include": "true"}, {"number": "22", "ReferenceId": "24263064", "FullCitation": "Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064", "Include": "true"}, {"number": "23", "ReferenceId": "32673682", "FullCitation": "Hayashi T, et al. Hum Pathol (2020) pmid: 32673682", "Include": "true"}, {"number": "24", "ReferenceId": "29780256", "FullCitation": "Cao L, et al. Onco Targets Ther (2018) pmid: 29780256", "Include": "true"}, {"number": "25", "ReferenceId": "21422421", "FullCitation": "Yang TY, et al. J. Clin. Oncol. (2011) pmid: 21422421", "Include": "true"}, {"number": "26", "ReferenceId": "23816960", "FullCitation": "Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960", "Include": "true"}, {"number": "27", "ReferenceId": "30127622", "FullCitation": "Qin BD, et al. Onco Targets Ther (2018) pmid: 30127622", "Include": "true"}, {"number": "28", "ReferenceId": "27131295", "FullCitation": "Frega S, et al. J Thorac Oncol (2016) pmid: 27131295", "Include": "true"}, {"number": "29", "ReferenceId": "33116645", "FullCitation": "Long X, et al. Onco Targets Ther (2020) pmid: 33116645", "Include": "true"}, {"number": "30", "ReferenceId": "29864379", "FullCitation": "Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379", "Include": "true"}, {"number": "31", "ReferenceId": "25923549", "FullCitation": "J\u00e4nne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549", "Include": "true"}, {"number": "32", "ReferenceId": "32749686", "FullCitation": "Hong MH, et al. Cancer (2020) pmid: 32749686", "Include": "true"}, {"number": "33", "ReferenceId": "26462025", "FullCitation": "Kim HS, et al. Oncotarget (2015) pmid: 26462025", "Include": "true"}, {"number": "34", "ReferenceId": "25424851", "FullCitation": "Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851", "Include": "true"}, {"number": "35", "ReferenceId": "32303840", "FullCitation": "Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840", "Include": "true"}, {"number": "36", "ReferenceId": "29734047", "FullCitation": "Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047", "Include": "true"}, {"number": "37", "ReferenceId": "32923886", "FullCitation": "Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886", "Include": "true"}, {"number": "38", "ReferenceId": "34339292", "FullCitation": "Park K, et al. J Clin Oncol (2021) pmid: 34339292", "Include": "true"}, {"number": "39", "ReferenceId": "35963523", "FullCitation": "Jatkoe T, et al. J Mol Diagn (2022) pmid: 35963523", "Include": "true"}, {"number": "40", "ReferenceId": "36246734", "FullCitation": "Petrini I, et al. Onco Targets Ther (2022) pmid: 36246734", "Include": "true"}, {"number": "41", "ReferenceId": "34548309", "FullCitation": "J\u00e4nne PA, et al. Cancer Discov (2021) pmid: 34548309", "Include": "true"}, {"number": "42", "ReferenceId": "29056570", "FullCitation": "Ahn MJ, et al. Lancet Respir Med (2017) pmid: 29056570", "Include": "true"}, {"number": "43", "ReferenceId": "27928026", "FullCitation": "Yang Z, et al. Sci Transl Med (2016) pmid: 27928026", "Include": "true"}, {"number": "44", "ReferenceId": "31587882", "FullCitation": "Ahn MJ, et al. Lancet Oncol (2019) pmid: 31587882", "Include": "true"}, {"number": "45", "ReferenceId": "35248866", "FullCitation": "Lin L, et al. Lung Cancer (2022) pmid: 35248866", "Include": "true"}, {"number": "46", "ReferenceId": "35580297", "FullCitation": "Lu S, et al. J Clin Oncol (2022) pmid: 35580297", "Include": "true"}, {"number": "47", "ReferenceId": "26175928", "FullCitation": "Chen JY, et al. Cancer Biol Med (2015) pmid: 26175928", "Include": "true"}, {"number": "48", "ReferenceId": "31911548", "FullCitation": "Schoenfeld AJ, et al. Clin. Cancer Res. (2020) pmid: 31911548", "Include": "true"}, {"number": "49", "ReferenceId": "30922878", "FullCitation": "Reck M, et al. Lancet Respir Med (2019) pmid: 30922878", "Include": "true"}, {"number": "50", "ReferenceId": "34311108", "FullCitation": "Socinski MA, et al. J Thorac Oncol (2021) pmid: 34311108", "Include": "true"}, {"number": "51", "ReferenceId": "29863955", "FullCitation": "Socinski MA, et al. N. Engl. J. Med. (2018) pmid: 29863955", "Include": "true"}, {"number": "52", "ReferenceId": "35908558", "FullCitation": "Lu S, et al. Lancet Oncol (2022) pmid: 35908558", "Include": "true"}, {"number": "53", "ReferenceId": "15950905", "FullCitation": "Samuels Y, et al. Cancer Cell (2005) pmid: 15950905", "Include": "true"}, {"number": "54", "ReferenceId": "19629070", "FullCitation": "Nat. Rev. Cancer (2009) pmid: 19629070", "Include": "true"}, {"number": "55", "ReferenceId": "15647370", "FullCitation": "Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370", "Include": "true"}, {"number": "56", "ReferenceId": "15930273", "FullCitation": "Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273", "Include": "true"}, {"number": "57", "ReferenceId": "17376864", "FullCitation": "Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864", "Include": "true"}, {"number": "58", "ReferenceId": "18317450", "FullCitation": "Horn S, et al. Oncogene (2008) pmid: 18317450", "Include": "true"}, {"number": "59", "ReferenceId": "21266528", "FullCitation": "Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528", "Include": "true"}, {"number": "60", "ReferenceId": "22120714", "FullCitation": "Hon WC, et al. Oncogene (2012) pmid: 22120714", "Include": "true"}, {"number": "61", "ReferenceId": "22949682", "FullCitation": "Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682", "Include": "true"}, {"number": "62", "ReferenceId": "19915146", "FullCitation": "Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146", "Include": "true"}, {"number": "63", "ReferenceId": "2103068", "FullCitation": "Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068", "Include": "true"}, {"number": "64", "ReferenceId": "20530683", "FullCitation": "Dan S, et al. Cancer Res. (2010) pmid: 20530683", "Include": "true"}, {"number": "65", "ReferenceId": "18829572", "FullCitation": "Oda K, et al. Cancer Res. (2008) pmid: 18829572", "Include": "true"}, {"number": "66", "ReferenceId": "18794883", "FullCitation": "Zhao L, et al. Oncogene (2008) pmid: 18794883", "Include": "true"}, {"number": "67", "ReferenceId": "23619167", "FullCitation": "Lui VW, et al. Cancer Discov (2013) pmid: 23619167", "Include": "true"}, {"number": "68", "ReferenceId": "22430209", "FullCitation": "Ross RL, et al. Oncogene (2013) pmid: 22430209", "Include": "true"}, {"number": "69", "ReferenceId": "22729224", "FullCitation": "Rivi\u00e8re JB, et al. Nat. Genet. (2012) pmid: 22729224", "Include": "true"}, {"number": "70", "ReferenceId": "19394761", "FullCitation": "Shibata T, et al. Cancer Lett. (2009) pmid: 19394761", "Include": "true"}, {"number": "71", "ReferenceId": "26627007", "FullCitation": "Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007", "Include": "true"}, {"number": "72", "ReferenceId": "29284706", "FullCitation": "Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706", "Include": "true"}, {"number": "73", "ReferenceId": "29533785", "FullCitation": "Ng PK, et al. Cancer Cell (2018) pmid: 29533785", "Include": "true"}, {"number": "74", "ReferenceId": "32929011", "FullCitation": "Spangle JM, et al. (2020) pmid: 32929011", "Include": "true"}, {"number": "75", "ReferenceId": "29636477", "FullCitation": "Chen L, et al. Nat Commun (2018) pmid: 29636477", "Include": "true"}, {"number": "76", "ReferenceId": "34779417", "FullCitation": "Jin N, et al. J Clin Invest (2021) pmid: 34779417", "Include": "true"}, {"number": "77", "ReferenceId": "27158780", "FullCitation": "Campbell JD, et al. Nat. Genet. (2016) pmid: 27158780", "Include": "true"}, {"number": "78", "ReferenceId": "24328409", "FullCitation": "Zhao Q, et al. Future Oncol (2014) pmid: 24328409", "Include": "true"}, {"number": "79", "ReferenceId": "26334752", "FullCitation": "Eng J, et al. J Thorac Oncol (2015) pmid: 26334752", "Include": "true"}, {"number": "80", "ReferenceId": "27554588", "FullCitation": "Song Z, et al. Cancer Med (2016) pmid: 27554588", "Include": "true"}, {"number": "81", "ReferenceId": "23674897", "FullCitation": "Zhang L, et al. Onco Targets Ther (2013) pmid: 23674897", "Include": "true"}, {"number": "82", "ReferenceId": "28024696", "FullCitation": "McGowan M, et al. Lung Cancer (2017) pmid: 28024696", "Include": "true"}, {"number": "83", "ReferenceId": "26107237", "FullCitation": "Wang Y, et al. Asian Pac. J. Cancer Prev. (2015) pmid: 26107237", "Include": "true"}, {"number": "84", "ReferenceId": "24608574", "FullCitation": "Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574", "Include": "true"}, {"number": "85", "ReferenceId": "29401002", "FullCitation": "Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002", "Include": "true"}, {"number": "86", "ReferenceId": "30793038", "FullCitation": "Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038", "Include": "true"}, {"number": "87", "ReferenceId": "34613809", "FullCitation": "Delestre F, et al. Sci Transl Med (2021) pmid: 34613809", "Include": "true"}, {"number": "88", "ReferenceId": "31619463", "FullCitation": "Morschhauser F, et al. Mol Cancer Ther (2020) pmid: 31619463", "Include": "true"}, {"number": "89", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "90", "ReferenceId": "31934607", "FullCitation": "Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607", "Include": "true"}, {"number": "91", "ReferenceId": "35133871", "FullCitation": "Damodaran S, et al. J Clin Oncol (2022) pmid: 35133871", "Include": "true"}, {"number": "92", "ReferenceId": "31091374", "FullCitation": "Andr\u00e9 F, et al. N. Engl. J. Med. (2019) pmid: 31091374", "Include": "true"}, {"number": "93", "ReferenceId": "33863913", "FullCitation": "Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913", "Include": "true"}, {"number": "94", "ReferenceId": "31351267", "FullCitation": "Varnier R, et al. Eur J Cancer (2019) pmid: 31351267", "Include": "true"}, {"number": "95", "ReferenceId": "32914004", "FullCitation": "Basse C, et al. JCO Precis Oncol (2018) pmid: 32914004", "Include": "true"}, {"number": "96", "ReferenceId": "33277683", "FullCitation": "Sultova E, et al. Arch Gynecol Obstet (2021) pmid: 33277683", "Include": "true"}, {"number": "97", "ReferenceId": "24166148", "FullCitation": "Mackay HJ, et al. Cancer (2014) pmid: 24166148", "Include": "true"}, {"number": "98", "ReferenceId": "27016228", "FullCitation": "Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228", "Include": "true"}, {"number": "99", "ReferenceId": "29588307", "FullCitation": "Dhami J, et al. Cold Spring Harb Mol Case Stud (2018) pmid: 29588307", "Include": "true"}, {"number": "100", "ReferenceId": "30863722", "FullCitation": "Harris EJ, et al. Front Oncol (2019) pmid: 30863722", "Include": "true"}, {"number": "101", "ReferenceId": "29301825", "FullCitation": "Hanna GJ, et al. Clin Cancer Res (2018) pmid: 29301825", "Include": "true"}, {"number": "102", "ReferenceId": "26098748", "FullCitation": "Vansteenkiste JF, et al. J Thorac Oncol (2015) pmid: 26098748", "Include": "true"}, {"number": "103", "ReferenceId": "15473860", "FullCitation": "Logan CY, et al. Annu. Rev. Cell Dev. Biol. (2004) pmid: 15473860", "Include": "true"}, {"number": "104", "ReferenceId": "11707392", "FullCitation": "Eklof Spink K, et al. EMBO J. (2001) pmid: 11707392", "Include": "true"}, {"number": "105", "ReferenceId": "16753179", "FullCitation": "Liu J, et al. J. Mol. Biol. (2006) pmid: 16753179", "Include": "true"}, {"number": "106", "ReferenceId": "20144988", "FullCitation": "Dikovskaya D, et al. J. Cell. Sci. (2010) pmid: 20144988", "Include": "true"}, {"number": "107", "ReferenceId": "17410430", "FullCitation": "Murphy SJ, et al. Dig. Dis. Sci. (2007) pmid: 17410430", "Include": "true"}, {"number": "108", "ReferenceId": "15459959", "FullCitation": "Aretz S, et al. Hum. Mutat. (2004) pmid: 15459959", "Include": "true"}, {"number": "109", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "110", "ReferenceId": "10549031", "FullCitation": "Sanz_Ortega J, et al. Pathol. Res. Pract. (1999) pmid: 10549031", "Include": "true"}, {"number": "111", "ReferenceId": "22542170", "FullCitation": "Poursoltan P, et al. Lung Cancer (2012) pmid: 22542170", "Include": "true"}, {"number": "112", "ReferenceId": "21255913", "FullCitation": "Zhang Y, et al. Cancer Lett. (2011) pmid: 21255913", "Include": "true"}, {"number": "113", "ReferenceId": "11448917", "FullCitation": "Virmani AK, et al. Clin. Cancer Res. (2001) pmid: 11448917", "Include": "true"}, {"number": "114", "ReferenceId": "16870044", "FullCitation": "Vallb\u00f6hmer D, et al. Clin Lung Cancer (2006) pmid: 16870044", "Include": "true"}, {"number": "115", "ReferenceId": "24309006", "FullCitation": "J. Natl. Cancer Inst. (2014) pmid: 24309006", "Include": "true"}, {"number": "116", "ReferenceId": "17194181", "FullCitation": "Lu Y, et al. PLoS Med. (2006) pmid: 17194181", "Include": "true"}, {"number": "117", "ReferenceId": "30635339", "FullCitation": "Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339", "Include": "true"}, {"number": "118", "ReferenceId": "27617575", "FullCitation": "Zhan T, et al. Oncogene (2017) pmid: 27617575", "Include": "true"}, {"number": "119", "ReferenceId": "32037398", "FullCitation": "Jung YS, et al. Exp Mol Med (2020) pmid: 32037398", "Include": "true"}, {"number": "120", "ReferenceId": "29169144", "FullCitation": "Krishnamurthy N, et al. Cancer Treat Rev (2018) pmid: 29169144", "Include": "true"}, {"number": "121", "ReferenceId": "33408116", "FullCitation": "Yamada K, et al. Cancer Res (2021) pmid: 33408116", "Include": "true"}, {"number": "122", "ReferenceId": "34837838", "FullCitation": "Kanda Y, et al. Biochem Biophys Res Commun (2022) pmid: 34837838", "Include": "true"}, {"number": "123", "ReferenceId": "23159591", "FullCitation": "Kerr SE, et al. J Mol Diagn (2013) pmid: 23159591", "Include": "true"}, {"number": "124", "ReferenceId": "21090969", "FullCitation": "Annu Rev Pathol (2011) pmid: 21090969", "Include": "true"}, {"number": "125", "ReferenceId": "18844223", "FullCitation": "Kastritis E, et al. Int. J. Cancer (2009) pmid: 18844223", "Include": "true"}, {"number": "126", "ReferenceId": "19822006", "FullCitation": "Half E, et al. Orphanet J Rare Dis (2009) pmid: 19822006", "Include": "true"}, {"number": "127", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "128", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "129", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "130", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "131", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "132", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "133", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "134", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "135", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "136", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "137", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "138", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "139", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "140", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "141", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "142", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "143", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "144", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "145", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "146", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "147", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "148", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "149", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "150", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "151", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "152", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "153", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "154", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "155", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "156", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "157", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "158", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "159", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "160", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "161", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "162", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "163", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "164", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "165", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "166", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "167", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "168", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "169", "ReferenceId": "32704382", "FullCitation": "Shan L, et al. Cell Discov (2020) pmid: 32704382", "Include": "true"}, {"number": "170", "ReferenceId": "20018398", "FullCitation": "Jin G, et al. Lung Cancer (2010) pmid: 20018398", "Include": "true"}, {"number": "171", "ReferenceId": "29337640", "FullCitation": "Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640", "Include": "true"}, {"number": "172", "ReferenceId": "21782507", "FullCitation": "O Byrne KJ, et al. Lancet Oncol. (2011) pmid: 21782507", "Include": "true"}, {"number": "173", "ReferenceId": "23136191", "FullCitation": "Spoerke JM, et al. Clin. Cancer Res. (2012) pmid: 23136191", "Include": "true"}, {"number": "174", "ReferenceId": "22982652", "FullCitation": "Yanagawa N, et al. J Thorac Oncol (2012) pmid: 22982652", "Include": "true"}, {"number": "175", "ReferenceId": "24284056", "FullCitation": "Cumberbatch M, et al. Clin. Cancer Res. (2014) pmid: 24284056", "Include": "true"}, {"number": "176", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "177", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "178", "ReferenceId": "23582881", "FullCitation": "Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881", "Include": "true"}, {"number": "179", "ReferenceId": "34246347", "FullCitation": "Sweeney C, et al. Lancet (2021) pmid: 34246347", "Include": "true"}, {"number": "180", "ReferenceId": "30037818", "FullCitation": "de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818", "Include": "true"}, {"number": "181", "ReferenceId": "27872130", "FullCitation": "Saura C, et al. Cancer Discov (2017) pmid: 27872130", "Include": "true"}, {"number": "182", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "183", "ReferenceId": "27091708", "FullCitation": "Andr\u00e9 F, et al. J. Clin. Oncol. (2016) pmid: 27091708", "Include": "true"}, {"number": "184", "ReferenceId": "31841354", "FullCitation": "Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354", "Include": "true"}, {"number": "185", "ReferenceId": "30302599", "FullCitation": "Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599", "Include": "true"}, {"number": "186", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "187", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "188", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "189", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "190", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "191", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "192", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "193", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "194", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "195", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "196", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "197", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "198", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "199", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "200", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "201", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "202", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "203", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "204", "ReferenceId": "26637197", "FullCitation": "Warth A, et al. Virchows Arch. (2016) pmid: 26637197", "Include": "true"}, {"number": "205", "ReferenceId": "16641899", "FullCitation": "Ninomiya H, et al. Br. J. Cancer (2006) pmid: 16641899", "Include": "true"}, {"number": "206", "ReferenceId": "29436178", "FullCitation": "Vanderwalde A, et al. Cancer Med (2018) pmid: 29436178", "Include": "true"}, {"number": "207", "ReferenceId": "31270941", "FullCitation": "Zang YS, et al. Cancer Med (2019) pmid: 31270941", "Include": "true"}, {"number": "208", "ReferenceId": "26880610", "FullCitation": "Dudley JC, et al. Clin. Cancer Res. (2016) pmid: 26880610", "Include": "true"}, {"number": "209", "ReferenceId": "28676214", "FullCitation": "Takamochi K, et al. Lung Cancer (2017) pmid: 28676214", "Include": "true"}, {"number": "210", "ReferenceId": "9329646", "FullCitation": "Pylkk\u00e4nen L, et al. Environ. Mol. Mutagen. (1997) pmid: 9329646", "Include": "true"}, {"number": "211", "ReferenceId": "11061602", "FullCitation": "Gonzalez R, et al. Ann. Oncol. (2000) pmid: 11061602", "Include": "true"}, {"number": "212", "ReferenceId": "8782463", "FullCitation": "Chen XQ, et al. Nat. Med. (1996) pmid: 8782463", "Include": "true"}, {"number": "213", "ReferenceId": "8174113", "FullCitation": "Merlo A, et al. Cancer Res. (1994) pmid: 8174113", "Include": "true"}, {"number": "214", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "215", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "216", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "217", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "218", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "219", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "220", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "221", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "222", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "223", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "224", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "225", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "226", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "227", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "228", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "229", "ReferenceId": "27197178", "FullCitation": "Colli LM, et al. Cancer Res. (2016) pmid: 27197178", "Include": "true"}, {"number": "230", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "231", "ReferenceId": "28923100", "FullCitation": "Wang VE, et al. J Immunother Cancer (2017) pmid: 28923100", "Include": "true"}, {"number": "232", "ReferenceId": "28636851", "FullCitation": "Carbone DP, et al. N. Engl. J. Med. (2017) pmid: 28636851", "Include": "true"}, {"number": "233", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "234", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "235", "ReferenceId": "29658848", "FullCitation": "Forde PM, et al. N. Engl. J. Med. (2018) pmid: 29658848", "Include": "true"}, {"number": "236", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "237", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "238", "ReferenceId": "30150660", "FullCitation": "Miao D, et al. Nat. Genet. (2018) pmid: 30150660", "Include": "true"}, {"number": "239", "ReferenceId": "30425022", "FullCitation": "Chae YK, et al. Clin Lung Cancer (2019) pmid: 30425022", "Include": "true"}, {"number": "240", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "241", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "242", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "243", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "244", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "245", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "246", "ReferenceId": "35113949", "FullCitation": "Meng G, et al. PLoS One (2022) pmid: 35113949", "Include": "true"}, {"number": "247", "ReferenceId": "31088500", "FullCitation": "Chen Y, et al. J. Exp. Clin. Cancer Res. (2019) pmid: 31088500", "Include": "true"}, {"number": "248", "ReferenceId": "30253973", "FullCitation": "Yu H, et al. J Thorac Oncol (2019) pmid: 30253973", "Include": "true"}, {"number": "249", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "250", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "251", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "252", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "253", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "254", "ReferenceId": "31562796", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2019) pmid: 31562796", "Include": "true"}, {"number": "255", "ReferenceId": "18650841", "FullCitation": "Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841", "Include": "true"}, {"number": "256", "ReferenceId": "19143056", "FullCitation": "Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056", "Include": "true"}, {"number": "257", "ReferenceId": "20594292", "FullCitation": "Berge EO, et al. Mol. Cancer (2010) pmid: 20594292", "Include": "true"}, {"number": "258", "ReferenceId": "16936740", "FullCitation": "Giacinti C, et al. Oncogene (2006) pmid: 16936740", "Include": "true"}, {"number": "259", "ReferenceId": "9342358", "FullCitation": "Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358", "Include": "true"}, {"number": "260", "ReferenceId": "10486322", "FullCitation": "Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322", "Include": "true"}, {"number": "261", "ReferenceId": "1534305", "FullCitation": "Qin XQ, et al. Genes Dev. (1992) pmid: 1534305", "Include": "true"}, {"number": "262", "ReferenceId": "16360038", "FullCitation": "Rubin SM, et al. Cell (2005) pmid: 16360038", "Include": "true"}, {"number": "263", "ReferenceId": "16449662", "FullCitation": "Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662", "Include": "true"}, {"number": "264", "ReferenceId": "22619677", "FullCitation": "Zhao W, et al. J Oncol (2012) pmid: 22619677", "Include": "true"}, {"number": "265", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "266", "ReferenceId": "30373917", "FullCitation": "Gong X, et al. Cancer Discov (2019) pmid: 30373917", "Include": "true"}, {"number": "267", "ReferenceId": "30373918", "FullCitation": "Oser MG, et al. Cancer Discov (2019) pmid: 30373918", "Include": "true"}, {"number": "268", "ReferenceId": "34741392", "FullCitation": "Yang W, et al. Kaohsiung J Med Sci (2022) pmid: 34741392", "Include": "true"}, {"number": "269", "ReferenceId": "30232224", "FullCitation": "Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224", "Include": "true"}, {"number": "270", "ReferenceId": "21955141", "FullCitation": "Allaman_Pillet N, et al. Ophthalmic Genet. () pmid: 21955141", "Include": "true"}, {"number": "271", "ReferenceId": "21875955", "FullCitation": "Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955", "Include": "true"}, {"number": "272", "ReferenceId": "24282159", "FullCitation": "Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159", "Include": "true"}, {"number": "273", "ReferenceId": "22553621", "FullCitation": "Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621", "Include": "true"}, {"number": "274", "ReferenceId": "21139478", "FullCitation": "Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478", "Include": "true"}, {"number": "275", "ReferenceId": "19959033", "FullCitation": "Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033", "Include": "true"}, {"number": "276", "ReferenceId": "35636696", "FullCitation": "Kenmotsu H, et al. J Thorac Oncol (2022) pmid: 35636696", "Include": "true"}, {"number": "277", "ReferenceId": "32139298", "FullCitation": "Oxnard GR, et al. Ann. Oncol. (2020) pmid: 32139298", "Include": "true"}, {"number": "278", "ReferenceId": "29151359", "FullCitation": "Soria JC, et al. N. Engl. J. Med. (2018) pmid: 29151359", "Include": "true"}, {"number": "279", "ReferenceId": "31751012", "FullCitation": "Ramalingam SS, et al. N. Engl. J. Med. (2019) pmid: 31751012", "Include": "true"}, {"number": "280", "ReferenceId": "33318755", "FullCitation": "Alanazi A, et al. Lung Cancer Manag (2020) pmid: 33318755", "Include": "true"}, {"number": "281", "ReferenceId": "30255937", "FullCitation": "Wang J, et al. Int. J. Cancer (2019) pmid: 30255937", "Include": "true"}, {"number": "282", "ReferenceId": "24501009", "FullCitation": "Reckamp KL, et al. Cancer (2014) pmid: 24501009", "Include": "true"}, {"number": "283", "ReferenceId": "25521398", "FullCitation": "Park K, et al. J Thorac Oncol (2014) pmid: 25521398", "Include": "true"}, {"number": "284", "ReferenceId": "32147669", "FullCitation": "van Geel RMJM, et al. Br. J. Cancer (2020) pmid: 32147669", "Include": "true"}, {"number": "285", "ReferenceId": "2986437", "FullCitation": "Opsomer RJ, et al. Acta Urol Belg (1985) pmid: 2986437", "Include": "true"}, {"number": "286", "ReferenceId": "28958502", "FullCitation": "Wu YL, et al. Lancet Oncol. (2017) pmid: 28958502", "Include": "true"}, {"number": "287", "ReferenceId": "26768165", "FullCitation": "Ramalingam SS, et al. Ann. Oncol. (2016) pmid: 26768165", "Include": "true"}, {"number": "288", "ReferenceId": "35693621", "FullCitation": "Li HS, et al. J Thorac Dis (2022) pmid: 35693621", "Include": "true"}, {"number": "289", "ReferenceId": "24439929", "FullCitation": "Wu YL, et al. Lancet Oncol. (2014) pmid: 24439929", "Include": "true"}, {"number": "290", "ReferenceId": "28376144", "FullCitation": "Lee CK, et al. J. Natl. Cancer Inst. (2017) pmid: 28376144", "Include": "true"}, {"number": "291", "ReferenceId": "28103612", "FullCitation": "Yang JJ, et al. Br. J. Cancer (2017) pmid: 28103612", "Include": "true"}, {"number": "292", "ReferenceId": "34388377", "FullCitation": "Zhou Q, et al. Cancer Cell (2021) pmid: 34388377", "Include": "true"}, {"number": "293", "ReferenceId": "34454653", "FullCitation": "Kawashima Y, et al. Lancet Respir Med (2022) pmid: 34454653", "Include": "true"}, {"number": "294", "ReferenceId": "30975627", "FullCitation": "Saito H, et al. Lancet Oncol (2019) pmid: 30975627", "Include": "true"}, {"number": "295", "ReferenceId": "20493771", "FullCitation": "Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771", "Include": "true"}, {"number": "296", "ReferenceId": "29687154", "FullCitation": "Faehling M, et al. J Cancer Res Clin Oncol (2018) pmid: 29687154", "Include": "true"}, {"number": "297", "ReferenceId": "31194613", "FullCitation": "Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613", "Include": "true"}, {"number": "298", "ReferenceId": "31591063", "FullCitation": "Nakagawa K, et al. Lancet Oncol. (2019) pmid: 31591063", "Include": "true"}, {"number": "299", "ReferenceId": "22056888", "FullCitation": "Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888", "Include": "true"}, {"number": "300", "ReferenceId": "20022809", "FullCitation": "Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809", "Include": "true"}, {"number": "301", "ReferenceId": "31553438", "FullCitation": "Yoshioka H, et al. Ann. Oncol. (2019) pmid: 31553438", "Include": "true"}, {"number": "302", "ReferenceId": "21670455", "FullCitation": "Fukuoka M, et al. J. Clin. Oncol. (2011) pmid: 21670455", "Include": "true"}, {"number": "303", "ReferenceId": "19692680", "FullCitation": "Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680", "Include": "true"}, {"number": "304", "ReferenceId": "27908825", "FullCitation": "Sutiman N, et al. J Thorac Oncol (2017) pmid: 27908825", "Include": "true"}, {"number": "305", "ReferenceId": "31411950", "FullCitation": "Noronha V, et al. J. Clin. Oncol. (2019) pmid: 31411950", "Include": "true"}, {"number": "306", "ReferenceId": "31682542", "FullCitation": "Hosomi Y, et al. J. Clin. Oncol. (2020) pmid: 31682542", "Include": "true"}, {"number": "307", "ReferenceId": "33012782", "FullCitation": "Creelan BC, et al. Br J Cancer (2021) pmid: 33012782", "Include": "true"}, {"number": "308", "ReferenceId": "22370314", "FullCitation": "Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314", "Include": "true"}, {"number": "309", "ReferenceId": "20573926", "FullCitation": "Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926", "Include": "true"}, {"number": "310", "ReferenceId": "25329826", "FullCitation": "Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826", "Include": "true"}, {"number": "311", "ReferenceId": "25546556", "FullCitation": "Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556", "Include": "true"}, {"number": "312", "ReferenceId": "26398831", "FullCitation": "Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831", "Include": "true"}, {"number": "313", "ReferenceId": "22452896", "FullCitation": "Miller VA, et al. Lancet Oncol. (2012) pmid: 22452896", "Include": "true"}, {"number": "314", "ReferenceId": "23816963", "FullCitation": "Katakami N, et al. J. Clin. Oncol. (2013) pmid: 23816963", "Include": "true"}, {"number": "315", "ReferenceId": "26156651", "FullCitation": "Soria JC, et al. Lancet Oncol. (2015) pmid: 26156651", "Include": "true"}, {"number": "316", "ReferenceId": "26646759", "FullCitation": "Schuler M, et al. Ann. Oncol. (2016) pmid: 26646759", "Include": "true"}, {"number": "317", "ReferenceId": "23664448", "FullCitation": "Chen X, et al. Lung Cancer (2013) pmid: 23664448", "Include": "true"}, {"number": "318", "ReferenceId": "25242668", "FullCitation": "Landi L, et al. Clin Lung Cancer (2014) pmid: 25242668", "Include": "true"}, {"number": "319", "ReferenceId": "25682316", "FullCitation": "De Gr\u00e8ve J, et al. Lung Cancer (2015) pmid: 25682316", "Include": "true"}, {"number": "320", "ReferenceId": "26051236", "FullCitation": "Yang JC, et al. Lancet Oncol. (2015) pmid: 26051236", "Include": "true"}, {"number": "321", "ReferenceId": "29110849", "FullCitation": "Horn L, et al. Lung Cancer (2017) pmid: 29110849", "Include": "true"}, {"number": "322", "ReferenceId": "31863283", "FullCitation": "Yamamoto N, et al. Adv Ther (2020) pmid: 31863283", "Include": "true"}, {"number": "323", "ReferenceId": "27083334", "FullCitation": "Park K, et al. Lancet Oncol (2016) pmid: 27083334", "Include": "true"}, {"number": "324", "ReferenceId": "28426106", "FullCitation": "Paz_Ares L, et al. Ann. Oncol. (2017) pmid: 28426106", "Include": "true"}, {"number": "325", "ReferenceId": "31178389", "FullCitation": "Lau SC, et al. Clin Lung Cancer (2019) pmid: 31178389", "Include": "true"}, {"number": "326", "ReferenceId": "31807143", "FullCitation": "Thongprasert S, et al. Lung Cancer Manag (2019) pmid: 31807143", "Include": "true"}, {"number": "327", "ReferenceId": "31637072", "FullCitation": "Llin\u00e1s_Quintero N, et al. Case Rep Oncol Med (2019) pmid: 31637072", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_01_11 20:31:20", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "390x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "8 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "LUNG", "disease_ontology": "Lung adenocarcinoma", "flowcell_analysis": "2000026857", "gender": "female", "pathology_diagnosis": "Lung Cancer; C34.9", "percent_tumor_nuclei": "20", "pipeline_version": "v3.18.0", "purity_assessment": "55.0", "specimen": "ORD_1537940_01*US1471012.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1537940_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Lung", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "390.79", "name": "SQ_US1471012.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.2805", "cds_effect": "2573T>G", "depth": "385", "equivocal": "false", "functional_effect": "missense", "gene": "EGFR", "percent_reads": "28.05", "position": "chr7:55259515", "protein_effect": "L858R", "status": "known", "strand": "+", "transcript": "NM_005228", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.4354", "cds_effect": "41A>G", "depth": "209", "equivocal": "false", "functional_effect": "missense", "gene": "SGK1", "percent_reads": "43.54", "position": "chr6:134496759", "protein_effect": "E14G", "status": "unknown", "strand": "_", "transcript": "NM_001143678", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.0439", "cds_effect": "3012G>A", "depth": "456", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "4.39", "position": "chr3:178951957", "protein_effect": "M1004I", "status": "known", "strand": "+", "subclonal": "true", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.4246", "cds_effect": "166C>G", "depth": "285", "equivocal": "false", "functional_effect": "missense", "gene": "PMS2", "percent_reads": "42.46", "position": "chr7:6043687", "protein_effect": "L56V", "status": "unknown", "strand": "_", "transcript": "NM_000535", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.2226", "cds_effect": "496_497TT>AC", "depth": "521", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CB", "percent_reads": "22.26", "position": "chr3:138461524", "protein_effect": "L166T", "status": "unknown", "strand": "_", "transcript": "NM_006219", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.4867", "cds_effect": "2089G>A", "depth": "376", "equivocal": "false", "functional_effect": "missense", "gene": "CD22", "percent_reads": "48.67", "position": "chr19:35835785", "protein_effect": "A697T", "status": "unknown", "strand": "+", "transcript": "NM_001771", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.2774", "cds_effect": "256G>A", "depth": "429", "equivocal": "false", "functional_effect": "missense", "gene": "EGFR", "percent_reads": "27.74", "position": "chr7:55211013", "protein_effect": "A86T", "status": "unknown", "strand": "+", "transcript": "NM_005228", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.2232", "cds_effect": "673G>A", "depth": "327", "equivocal": "false", "functional_effect": "missense", "gene": "POLE", "percent_reads": "22.32", "position": "chr12:133254211", "protein_effect": "D225N", "status": "unknown", "strand": "_", "transcript": "NM_006231", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.5136", "cds_effect": "1523G>A", "depth": "294", "equivocal": "false", "functional_effect": "missense", "gene": "MEN1", "percent_reads": "51.36", "position": "chr11:64572131", "protein_effect": "G508D", "status": "unknown", "strand": "_", "transcript": "NM_130801", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.505", "cds_effect": "1699A>G", "depth": "299", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "50.5", "position": "chr9:139410139", "protein_effect": "I567V", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.3204", "cds_effect": "6887G>A", "depth": "309", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "32.04", "position": "chr5:112178178", "protein_effect": "S2296N", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.0205", "cds_effect": "3883G>T", "depth": "341", "equivocal": "false", "functional_effect": "nonsense", "gene": "APC", "percent_reads": "2.05", "position": "chr5:112175174", "protein_effect": "E1295*", "status": "known", "strand": "+", "subclonal": "true", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.446", "cds_effect": "874G>A", "depth": "352", "equivocal": "false", "functional_effect": "missense", "gene": "RET", "percent_reads": "44.6", "position": "chr10:43601830", "protein_effect": "V292M", "status": "unknown", "strand": "+", "transcript": "NM_020975", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.4481", "cds_effect": "1381C>T", "depth": "212", "equivocal": "false", "functional_effect": "missense", "gene": "CDH1", "percent_reads": "44.81", "position": "chr16:68849478", "protein_effect": "P461S", "status": "unknown", "strand": "+", "transcript": "NM_004360", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.2751", "cds_effect": "679G>T", "depth": "378", "equivocal": "false", "functional_effect": "nonsense", "gene": "MED12", "percent_reads": "27.51", "position": "chrX:70340946", "protein_effect": "E227*", "status": "unknown", "strand": "+", "transcript": "NM_005120", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.2483", "cds_effect": "4795C>T", "depth": "149", "equivocal": "false", "functional_effect": "missense", "gene": "CIC", "percent_reads": "24.83", "position": "chr19:42799311", "protein_effect": "P1599S", "status": "unknown", "strand": "+", "transcript": "NM_015125", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.582", "cds_effect": "1256A>T", "depth": "488", "equivocal": "false", "functional_effect": "missense", "gene": "BCL6", "percent_reads": "58.2", "position": "chr3:187446937", "protein_effect": "E419V", "status": "unknown", "strand": "_", "transcript": "NM_001706", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"allele_fraction": "0.4104", "cds_effect": "353G>A", "depth": "385", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "41.04", "position": "chr3:178917478", "protein_effect": "G118D", "status": "known", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "6", "equivocal": "true", "gene": "SDHA", "number_of_exons": "15 of 15", "position": "chr5:218437_256556", "ratio": "2.48", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "RB1", "number_of_exons": "14 of 27", "position": "chr13:48953693_49201170", "ratio": "0.44", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"copy_number": "6", "equivocal": "true", "gene": "NPM1", "number_of_exons": "12 of 12", "position": "chr5:170798557_170842532", "ratio": "2.16", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "PTEN", "number_of_exons": "2 of 9", "position": "chr10:89548329_89657280", "ratio": "0.45", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1471012.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "8.45", "status": "intermediate", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}